High-energy breast milk diets for extremely preterm infants
Part of Genetic & congenital, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests whether feeding extremely premature babies (born at 28 weeks or earlier) a higher-energy breast milk diet in the first two weeks of life can reduce the risk of bronchopulmonary dysplasia (BPD), a serious lung condition. It aims to find a safe and effective way to support lung development in these tiny infants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be born at or before 28 weeks of pregnancy.
- Your baby must be less than 72 hours old.
- Your baby cannot have any major birth defects.
- Your baby cannot have genetic abnormalities.
- Your baby must not have a terminal illness where life support is limited or withdrawn.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving intravenous immunoglobulin (IVIG) early after birth can help prevent or treat a serious lung condition called bronchopulmonary dysplasia (BPD) in babies born at 28 weeks or earlier. It may help reduce the need for breathing support and oxygen.
This study tests a special high-energy formula for babies with congenital heart disease who are at nutritional risk. It aims to see if this feeding helps them grow and develop better before and after heart surgery.
This study tests whether a special cell therapy (MSC-EVs) given to extremely premature babies can help prevent a serious lung disease called bronchopulmonary dysplasia (BPD). The treatment is given while the baby is still on a breathing machine.
This study compares two ways of feeding premature babies with lung disease (BPD) who still need breathing support: feeding through a tube into the stomach (gastric) versus past the stomach into the small intestine (transpyloric). The goal is to see which feeding method helps these babies grow better and avoid problems.
This trial tests if intravenous immunoglobulin (IVIG) can help prevent or treat bronchopulmonary dysplasia (BPD), a lung condition in premature babies. It is for very preterm infants born between 25 and 29 weeks who show early signs of BPD and are enrolled in the first day of life.
This trial tests a standardized, team-agreed discharge plan to help preterm babies with lung disease (often called BPD) leave the hospital safely. It may help by making the discharge process more consistent, especially for babies going home on breathing support like oxygen.
Hear when a new Extreme Prematurity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.